D rug-induced autoimmune hepatitis (DIAIH) is an increasingly recognized phenotype of druginduced liver injury (DILI). [1] [2] [3] There are few data on treatment of patients with DIAIH. 3 We aimed to determine the frequency of DIAIH in Iceland, its causative agents, response to corticosteroids, and risk of relapse.
Methods
Most patients had been prior participants in previous studies. 2, 4, 5 Inclusion criteria were a drug reaction with well-documented cause of DIAIH, with positive antinuclear antibodies and/or smooth muscle antibodies and/ or elevated IgG; 10 times above the upper limit of normal elevation in alanine aminotransferase with a hepatocellular or mixed pattern; or requirement of corticosteroids in patients with hepatocellular type of injury, the latter defined as no improvement in alanine aminotransferase and aspartate aminotransferase after discontinuation of the implicated agent. Roussel Uclaf Causality Assessment Method was used for causality assessment of suspected DILI. 6 The new simplified criteria for autoimmune hepatitis (AIH) were calculated. 7 
Results
In the present study 93% of the patients were of female gender, similar to other DIAIH studies. 1, 3 During the study period 18 patients developed liver injury with drugs known to lead to immune-mediated reactions. Overall 14 were treated with tumor necrosis factor-a inhibitors; 3 did not fulfill the inclusion criteria because they had cholestatic pattern (n ¼ 2) or with alanine aminotransferase only elevated 7 times upper limit of normal and without markers of autoimmunity. Overall 11 patients with infliximab-induced liver injury, 3 with nitrofurantoin, and 1 with imatinib-induced liver injury were included (Table 1) . A total of 93% had hepatocellular injury, 53% jaundice, but none had coagulopathy. Roussel Uclaf Causality Assessment Method showed 12 patients had a probable causal relationship, 1 highly probable, and 2 possible. New simplified criteria for AIH showed 6 patients had at least probable AIH (>6 points). Fourteen patients had elevated antinuclear antibodies, but none had positive smooth muscle antibodies. Biopsies (n ¼ 6) showed acute hepatitis with mixed inflammatory pattern, and severe inflammation (n ¼ 4); none had prominent fibrosis. The most common histologic pattern was dropout of liver cells in the periportal area but there were no distinguishing features between DILI and AIH. Six patients had spontaneous improvement in liver tests after discontinuation of the implicated agent. Nine were treated with corticosteroids, with 30 (n ¼ 5) or 40 mg (n ¼ 4) following a median of 70 days (range, 7-90 days) after detection of elevated liver tests, (mean of 4 months, range, 4-6 months). All responded with normalization of aminotransferases after a mean of 154 days (range, 80-300). Steroids were discontinued in all patients and none showed signs of biochemical relapse after a median follow-up of 4.1 years (range, 0.5-6.0). Overall 8 out of 11 infliximab-treated patients were switched to another tumor necrosis factor-a inhibitor, adalimumab in 5 and ethanercept in 5 without evidence of liver injury during follow-up.
Discussion
In line with other reports the duration of drug therapy leading to DIAH was longer than in other patients with DILI with frequent autoimmune features. 5 Overall 93% had elevated antinuclear antibodies and 40% IgG elevation. The main differential diagnoses were DILI and AIH. In the DILIN cohort the drugs were different because minocycline, methyldopa, and hydralizine are not marketed in Iceland. 3 Overall 40% showed spontaneous improvement in liver tests after discontinuation of the implicated drugs. Analysis of the liver biopsies of our patients revealed that it was very difficult to distinguish between histologic features that favored DILI and those favoring AIH potentially requiring steroids. Thus, liver biopsies did not seem to guide therapy. These results are in line with a study of the use of liver histology in discrimination between DILI and AIH. 7 The results of the current study do not suggest that liver histology is likely to change management. Some of the patients not fulfilling the new simplified criteria for AIH clearly required corticosteroids. Patients who did not improve in liver tests after discontinuation of the drug leading to the immune reactions were treated with corticosteroids, all of whom had a prompt response to corticosteroids. After approximately 4 years none of the patients showed a sign of a clinical or biochemical relapse after discontinuation of corticosteroids. This is in line with other studies showing lack of a relapse when immunosuppression has been stopped, 1 which is very unusual in patients with genuine AIH. 7 Infliximab was the most common cause of DIAIH and on recovery patients tolerated treatment with another tumor necrosis factor inhibitor well. It is conceivable that DIAIH is on the rise in the western world because of the wider use of infliximab. However, currently good epidemiologic studies that have demonstrated this are lacking. 
